# Jordi Mata-Fink

> Jordi Mata-Fink is the co-founder and CEO of Gate Bioscience, a Brisbane, California biotech building an entirely new class of small-molecule drugs called Molecular Gates. The idea is deceptively simple and technically audacious: instead of chasing disease-causing proteins after they leave the cell, Gate's molecules park inside the cell's secretory channel (Sec61) and selectively stop a single harmful protein from ever getting out, while letting everything else pass. A chemical engineer trained at Stanford and MIT, Mata-Fink spent years inside Flagship Pioneering helping spin up companies like Editas and Rubius before founding Gate in 2021. The company emerged from stealth in 2023 with $60M, and in November 2025 raised an oversubscribed $65M Series B led by Forbion with Eli Lilly joining, pushing total funding to $135M as it heads toward the clinic. He coaches youth soccer on the side.

- **Role:** Co-Founder and CEO at Gate Bioscience
- **Organizations:** Gate Bioscience, Flagship Pioneering, Generate Biomedicines, Cygnal Therapeutics, Rubius Therapeutics, Editas Medicine
- **Nationality:** American
- **Education:** B.S. in Chemical Engineering, Stanford University, M.S. in Chemical Engineering, Stanford University, Ph.D. in Chemical Engineering (protein engineering for vaccines and immunotherapies), Massachusetts Institute of Technology (MIT)
- **Known for:** Co-founded and leads Gate Bioscience, creator of Molecular Gates, a new class of small-molecule medicines, Raised $135M total across Series A and B from Forbion, Eli Lilly, Versant Ventures, a16z Bio + Health, GV and ARCH Venture Partners, Helped build multiple Flagship Pioneering companies including Editas Medicine and Rubius Therapeutics

## Career timeline

- **2013** — Joined Flagship Pioneering; founding team member at Editas Medicine
- **2013-2017** — Founder and Director of Discovery at Rubius Therapeutics
- **2016-2019** — Founder and CTO of Cygnal Therapeutics
- **2018-2020** — Part of the founding team at Generate Biomedicines
- **2021** — Co-founded Gate Bioscience and became CEO
- **2023** — Gate Bioscience emerged from stealth with $60M Series A and introduced Molecular Gates
- **2025** — Closed an oversubscribed $65M Series B led by Forbion with Eli Lilly joining; total funding reaches $135M

## Achievements

- Co-founded and leads Gate Bioscience, creator of Molecular Gates, a new class of small-molecule medicines
- Raised $135M total across Series A and B from Forbion, Eli Lilly, Versant Ventures, a16z Bio + Health, GV and ARCH Venture Partners
- Helped build multiple Flagship Pioneering companies including Editas Medicine and Rubius Therapeutics
- Earned a Ph.D. in Chemical Engineering from MIT specializing in protein engineering for vaccines and immunotherapies

## Latest updates

- **2025-11** — Gate Bioscience announced an oversubscribed $65M Series B led by Forbion, with Eli Lilly joining alongside Versant, a16z Bio + Health, GV and ARCH, bringing total funding to $135M to push lead programs toward the clinic.
- **2025-10** — Mata-Fink shared a milestone for Gate Bioscience's Molecular Gates platform on LinkedIn, citing maturation of the discovery engine.

## Links

- Website: https://gatebio.com
- LinkedIn: https://www.linkedin.com/in/jordi-mata-fink-8a677918

---

Profile page: https://yespress.io/jordi-mata-fink
Published by YesPress — https://yespress.io
Last updated: 2026-06-11